Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma

Sabry, H.H.; Sorour, N.E.; Akl, E.M.

doi:10.1080/09546634.2019.1590521

Cited by 11 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, intralesional injections of corticosteroids and sclerotherapy are two important methods for the clinical treatment of IH, and their effectiveness has also been demonstrated. [13][14][15][16][17][18] Since 1967, the local anesthetic polidocanol has been used for sclerotherapy 18 with several advantages, such as the local anesthetic effect alleviating pain during the injection, low toxicity and low risk of allergic reaction. 19 Lauromacrogol produced in China has been approved for use since 2008.…”

Section: Discussionmentioning

confidence: 99%

Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas

Chai

Zhou

Song

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

The efficacy of lauromacrogol injection therapy and intralesional triamcinolone for infantile hemangiomas (IH) has been well documented recently, but with an increase in serious or rare adverse reactions. The aim of this study is to investigate the safety concerns regarding intralesional injection of lauromacrogol combined with triamcinolone for IH and to study its effect on infant growth and development. A total of 1039 IH patients who were subjected to intralesional injection of lauromacrogol combined with triamcinolone in the Plastic Surgery Department of Shandong Provincial Hospital between 1 January 2015 and 31 May 2018 were enrolled in this study. When the dose of lauromacrogol and triamcinolone was less than 3.5 and 2.0 mg/kg respectively, no serious side‐effects were observed. The adverse event rate reported was 7.7%. Among the 405 patients not subjected to propranolol before the last injection, the study included three modes of treatment response: regression (82.7%), stabilization (13.8%) and failure (3.5%). By comparing height and weight to the reference standards and also by comparisons between the same‐sex groups, our results confirmed that there was no significant effect on children's height and weight, regardless of whether the injection therapy was combined with oral propranolol at the appropriate dose and with more than 4‐week intervals. Intralesional injection of lauromacrogol combined with triamcinolone in the treatment of IH was highly safe and effective.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas

Chai

Zhou

Song

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Vincristine, a chemotherapy, that induces apoptosis of endothelial cells has been shown to be effective as a single weekly dose of 1–1.5 mg/m 2 , 26,27 However, there are significant side effects which include constipation and neuropathy 26,27 . There are several reports on resistant IHs being treated successfully with intralesional bevacizumab 28,29 . Further trials or systematic reviews are needed to determine if this is a safe and effective second‐line treatment for IHs.…”

Section: Multimodal Approachmentioning

confidence: 99%

“…26,27 There are several reports on resistant IHs being treated successfully with intralesional bevacizumab. 28,29 Further trials or systematic reviews are needed to determine if this is a safe and effective second-line treatment for IHs.…”

Section: Multimodal Approachmentioning

confidence: 99%

Multimodality treatment of vascular anomalies of the head and neck

Dorrity

Mack

Wong

et al. 2022

J Oral Pathology Medicine

View full text Add to dashboard Cite

Background: Vascular anomalies affect up to 5% of children with the majority affecting the head and neck. They present at different ages as a wide variety of lesions. A careful evaluation with history, physical examination, and imaging assists in the proper diagnosis. Depending upon the condition treatment options for vascular anomalies include topical therapy, selective photothermolysis, sclerotherapy, embolization, surgical excision, and targeted systemic therapy. Conclusion:Staged multimodal therapeutic regimens have proven to best control disease and allow for the preservation of function and aesthetics. The timing, sequence, and combination of therapies are best determined by a multidisciplinary vascular anomalies team. Patients and families need to be counseled on anticipated positive outcomes following a protracted course of treatment for the majority of vascular anomalies.

show abstract

“…VEGF is a potent proangiogenic factor facilitating endothelial cell survival, migration, and proliferation [10]. Previous studies have also demonstrated the expression of VEGF in keloid scars [10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Bevacizumab as Adjuvant Therapy in the Treatment of Keloid: A Randomized Clinical Trial

Shahmoradi,

Khalili-Tembi,

Faghihi

et al. 2024

Dermatologic Therapy

View full text Add to dashboard Cite

Background. Despite the availability of numerous therapies, keloid treatment remains a challenging clinical issue. Intralesional triamcinolone has been established as an effective corticosteroid treatment for keloids, while sporadic reports suggest the efficacy of intralesional verapamil. This study aimed to evaluate the safety and efficacy of bevacizumab as an adjuvant therapy for keloid treatment. Methods. This randomized controlled trial involved 38 patients diagnosed with keloid according to clinical criteria. The study compared the effects of intralesional triamcinolone combined with bevacizumab injections with intralesional triamcinolone alone. Patients were randomly assigned to either the combination treatment group, which received intralesional triamHEXAL® (20 mg/ml, every two weeks for three months) plus Avastin® (2.5 mg/ml, every two weeks for two months), or the single treatment group, which received intralesional triamHEXAL® alone. The Vancouver Scar Scale (VSS) was used for serial photographic records of scar evaluation, with differences in VSS scores considered the primary outcome, and changes in height and patient satisfaction visual analog score (VAS) were secondary outcomes. Results. A total of 38 patients participated, with a mean age (SD) of 35.32 (14.02) years and 50% male. No significant differences in age, BMI, disease duration, gender, causing, family history, or site were observed between the two groups. The single treatment group exhibited a mean reduction of 0.60 (95% CI: (−1.18, −0.01); P=0.045) in pigmentation score and a mean decrease of 1.37 (95% CI: (−2.68, −0.07); P=0.039) in total score compared to the combination treatment group after three months of treatment. There was a significant reduction in keloid height in the combination group after the end of the treatment (P=0.024). No significant differences in side effects were observed between the two groups. Conclusion. Our study demonstrates that bevacizumab can be considered an effective and safe adjuvant therapy option for keloid treatment, suggesting its potential as a promising treatment for the management of keloids. This trial is registered with IRCT20131119015455N5.

show abstract

Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma

Cited by 11 publications

References 23 publications

Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas

Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas

Multimodality treatment of vascular anomalies of the head and neck

Bevacizumab as Adjuvant Therapy in the Treatment of Keloid: A Randomized Clinical Trial

Contact Info

Product

Resources

About